Thrombophilia primary prevention

Jump to navigation Jump to search

Thrombophilia Microchapters


Patient Information


Historical Perspective




Differentiating Thrombophilia from other Diseases

Epidemiology and Demographics

Risk Factors


Natural History, Complications and Prognosis


History and Symptoms

Physical Examination

Laboratory Findings

X Ray




Other Imaging Findings

Other Diagnostic Studies


Medical Therapy


Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Thrombophilia primary prevention On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides


American Roentgen Ray Society Images of Thrombophilia primary prevention

All Images
Echo & Ultrasound
CT Images

Ongoing Trials at Clinical

US National Guidelines Clearinghouse

NICE Guidance

FDA on Thrombophilia primary prevention

CDC on Thrombophilia primary prevention

Thrombophilia primary prevention in the news

Blogs on Thrombophilia primary prevention

Directions to Hospitals Treating Thrombophilia

Risk calculators and risk factors for Thrombophilia primary prevention

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Asiri Ediriwickrema, M.D., M.H.S. [2] Jaspinder Kaur, MBBS[3]


Thromboprophylaxis with anticoagulation may be recommended for primary prevention of acute thrombosis in high risk acquired and inherited thrombophilias.[1][2][3][4][5][6]

Primary Prevention

  • Thrombosis Prevention:
    • There is no evidence to support the long-term pharmacological primary thromboprophylaxis of asymptomatic family members found to have a thrombophilic genotype.
    • Additionally, patients who experience a thrombotic event towards the end of their period of anticoagulant treatment course should be counseled about the signs and symptoms of thromboembolism and made aware about the requirement to seek an early medical attention on suspicion of a recurrence.
    • Moreover, they should be advised to mention their history of VTE to their physicians so that appropriate decisions about short-term thromboprophylaxis at times of increased thrombotic risk can be made.
    • Hence, all patients with a past history of VTE with or without evidence of a thrombophilic defect merit consideration for short-term thromboprophylaxis to cover periods of increased thrombotic risk such as surgery, trauma, plaster casts or immobilization.
Table 1: Enlist the indications for thromboprophylaxis with anticoagulation[1][2][3][4][5][6]
Indications for thromboprophylaxis


  1. 1.0 1.1 DeLoughery TG. Hemostasis and Thrombosis: Springer International Publishing; 2014.
  2. 2.0 2.1 Cohoon KP, Heit JA (2014). "Inherited and secondary thrombophilia". Circulation. 129 (2): 254–7. doi:10.1161/CIRCULATIONAHA.113.001943. PMC 3979345. PMID 24421360.
  3. 3.0 3.1 Seligsohn U, Lubetsky A (2001). "Genetic susceptibility to venous thrombosis". N Engl J Med. 344 (16): 1222–31. doi:10.1056/NEJM200104193441607. PMID 11309638.
  4. 4.0 4.1 Falck-Ytter Y, Francis CW, Johanson NA, Curley C, Dahl OE, Schulman S; et al. (2012). "Prevention of VTE in orthopedic surgery patients: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines". Chest. 141 (2 Suppl): e278S–325S. doi:10.1378/chest.11-2404. PMC 3278063. PMID 22315265.
  5. 5.0 5.1 Bergqvist D, Agnelli G, Cohen AT, Eldor A, Nilsson PE, Le Moigne-Amrani A; et al. (2002). "Duration of prophylaxis against venous thromboembolism with enoxaparin after surgery for cancer". N Engl J Med. 346 (13): 975–80. doi:10.1056/NEJMoa012385. PMID 11919306.
  6. 6.0 6.1 Agnelli G (2004). "Prevention of venous thromboembolism in surgical patients". Circulation. 110 (24 Suppl 1): IV4–12. doi:10.1161/01.CIR.0000150639.98514.6c. PMID 15598646.

Template:WH Template:WS